TY - JOUR T1 - While hormone therapy unlikely harmful in younger postmenopausal women at low CV risk, protective effects cannot be claimed JF - Evidence Based Medicine JO - Evid Based Med SP - 176 LP - 177 DO - 10.1136/eb-2012-101127 VL - 18 IS - 5 AU - Beth L Abramson Y1 - 2013/10/01 UR - http://ebm.bmj.com/content/18/5/176.abstract N2 - Commentary on: Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.OpenUrlAbstract/FREE Full Text The last 10 years have clarified the issues regarding postmenopausal hormone therapy (HT) and cardiovascular disease (CVD). Prior to the large, randomised women's health initiative (WHI),1 observational studies had suggested a protective cardiovascular (CV) effect. The WHI showed no benefit, and increased thromboembolic and CV events in women taking HT. The WHI findings have been challenged because of the older age of the participants.2 A ‘critical timing’ hypothesis has been suggested to try to explain how the use of HT at the onset of menopause could be cardioprotective, whereas later initiation could cause adverse events.3– ,6 … ER -